For the quarter ending 2025-09-30, CLRB has $14,627,590 in assets. $5,248,261 in debts. $12,554,289 in cash and cash equivalents.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 12,554,289 | 11,041,027 | ||
| Prepaid expenses and other current assets | 1,067,409 | 1,576,579 | ||
| Total current assets | 13,621,698 | 12,617,606 | ||
| Property, plant & equipment, net | 595,271 | 647,549 | ||
| Operating lease right-of-use asset | 380,841 | 400,248 | ||
| Other long-term assets | 29,780 | 29,780 | ||
| Total assets | 14,627,590 | 13,695,183 | ||
| Accounts payable and accrued liabilities | 4,014,682 | 4,678,713 | ||
| Warrant liability | 801,650 | 1,095,926 | ||
| Lease liability, current | 96,034 | 92,022 | ||
| Total current liabilities | 4,912,366 | 5,866,661 | ||
| Lease liability, net of current portion | 335,895 | 361,487 | ||
| Total liabilities | 5,248,261 | 6,228,148 | ||
| Series d preferred stock, 111.11 shares authorized, issued and outstanding as of september 30, 2025 and december 31, 2024-Series DConvertible Preferred Stock | 1,382,023 | 1,382,023 | ||
| Series e-2 preferred stock, 1,225 shares authorized 35.60 shares issued and outstanding as of september 30, 2025 and december 31, 2024, respectively | 520,778 | 520,778 | ||
| Common stock, 0.00001 par value 170,000,000 shares authorized 3,192,040 and 1,535,996 shares issued and outstanding as of september 30, 2025 and december 31, 2024, respectively | 32 | 18 | ||
| Additional paid-in capital | 271,314,776 | 264,958,619 | ||
| Accumulated deficit | -263,838,280 | -259,394,403 | ||
| Total stockholders' equity | 7,997,306 | 6,085,012 | ||
| Total liabilities and stockholders' equity | 14,627,590 | 13,695,183 | ||
Cellectar Biosciences, Inc. (CLRB)
Cellectar Biosciences, Inc. (CLRB)